Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers.
Aguilar C, Lenoir C, Lambert N, Bègue B, Brousse N, Canioni D, Berrebi D, Roy M, Gérart S, Chapel H, Schwerd T, Siproudhis L, Schäppi M, Al-Ahmari A, Mori M, Yamaide A, Galicier L, Neven B, Routes J, Uhlig HH, Koletzko S, Patel S, Kanegane H, Picard C, Fischer A, Bensussan NC, Ruemmele F, Hugot JP, Latour S. Aguilar C, et al. Among authors: siproudhis l. J Allergy Clin Immunol. 2014 Nov;134(5):1131-41.e9. doi: 10.1016/j.jaci.2014.04.031. Epub 2014 Jun 15. J Allergy Clin Immunol. 2014. PMID: 24942515 Clinical Trial.
Anal lesions: any significant prognosis in Crohn's disease?
Siproudhis L, Mortaji A, Mary JY, Juguet F, Bretagne JF, Gosselin M. Siproudhis L, et al. Eur J Gastroenterol Hepatol. 1997 Mar;9(3):239-43. doi: 10.1097/00042737-199703000-00004. Eur J Gastroenterol Hepatol. 1997. PMID: 9096423
NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype- phenotype analysis.
Heresbach D, Gicquel-Douabin V, Birebent B, D'halluin PN, Heresbach-Le Berre N, Dreano S, Siproudhis L, Dabadie A, Gosselin M, Mosser J, Semana G, Bretagne JF, Yaouanq J. Heresbach D, et al. Among authors: siproudhis l. Eur J Gastroenterol Hepatol. 2004 Jan;16(1):55-62. doi: 10.1097/00042737-200401000-00009. Eur J Gastroenterol Hepatol. 2004. PMID: 15095853
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Bouguen G, et al. Among authors: siproudhis l. Inflamm Bowel Dis. 2015 May;21(5):1047-53. doi: 10.1097/MIB.0000000000000359. Inflamm Bowel Dis. 2015. PMID: 25803504
Crohn's disease: is there any link between anal and luminal phenotypes?
Wallenhorst T, Brochard C, Bretagne JF, Bouguen G, Siproudhis L. Wallenhorst T, et al. Among authors: siproudhis l. Int J Colorectal Dis. 2016 Feb;31(2):307-11. doi: 10.1007/s00384-015-2390-8. Epub 2015 Sep 26. Int J Colorectal Dis. 2016. PMID: 26410258 Free article.
234 results